Pacer Advisors Inc. Has $144.42 Million Stock Position in United Therapeutics Corporation $UTHR

Pacer Advisors Inc. lifted its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 0.7% in the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 243,545 shares of the biotechnology company’s stock after buying an additional 1,673 shares during the period. Pacer Advisors Inc.’s holdings in United Therapeutics were worth $144,417,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also modified their holdings of the company. Parallel Advisors LLC grew its position in United Therapeutics by 2.8% in the first quarter. Parallel Advisors LLC now owns 1,056 shares of the biotechnology company’s stock valued at $626,000 after acquiring an additional 29 shares during the last quarter. NewEdge Advisors LLC lifted its holdings in shares of United Therapeutics by 24.7% in the first quarter. NewEdge Advisors LLC now owns 2,163 shares of the biotechnology company’s stock worth $1,283,000 after acquiring an additional 428 shares during the last quarter. Janus Henderson Group PLC lifted its holdings in shares of United Therapeutics by 8.9% in the first quarter. Janus Henderson Group PLC now owns 866,930 shares of the biotechnology company’s stock worth $514,016,000 after acquiring an additional 70,829 shares during the last quarter. Bull Harbor Capital LLC acquired a new stake in shares of United Therapeutics in the 1st quarter valued at approximately $494,000. Finally, Strategic Investment Advisors MI boosted its stake in shares of United Therapeutics by 20.5% in the 1st quarter. Strategic Investment Advisors MI now owns 9,752 shares of the biotechnology company’s stock valued at $5,782,000 after purchasing an additional 1,662 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors.

Insider Activity at United Therapeutics

In other United Therapeutics news, EVP Paul A. Mahon sold 8,300 shares of the stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $552.56, for a total transaction of $4,586,248.00. Following the completion of the sale, the executive vice president owned 45,172 shares of the company’s stock, valued at approximately $24,960,240.32. This represents a 15.52% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Martine A. Rothblatt sold 9,500 shares of the firm’s stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $522.37, for a total transaction of $4,962,515.00. Following the transaction, the chief executive officer owned 324,443 shares of the company’s stock, valued at approximately $169,479,289.91. The trade was a 2.84% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 483,333 shares of company stock worth $268,126,647 over the last ninety days. Insiders own 8.60% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on UTHR shares. Morgan Stanley set a $516.00 price objective on shares of United Therapeutics in a research report on Thursday, May 7th. Wells Fargo & Company upgraded shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $575.00 to $735.00 in a research report on Thursday, May 7th. Bank of America decreased their target price on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research note on Friday, July 10th. Royal Bank Of Canada upped their price target on shares of United Therapeutics from $701.00 to $704.00 and gave the stock an “outperform” rating in a report on Tuesday, July 7th. Finally, Weiss Ratings cut United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research note on Friday. Eleven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $648.33.

United Therapeutics Stock Performance

Shares of UTHR opened at $517.71 on Monday. The stock’s 50-day moving average price is $543.63 and its two-hundred day moving average price is $532.79. United Therapeutics Corporation has a 12 month low of $272.12 and a 12 month high of $609.35. The company has a market capitalization of $21.98 billion, a PE ratio of 19.11, a PEG ratio of 1.73 and a beta of 0.59.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The company had revenue of $781.50 million during the quarter, compared to analyst estimates of $797.40 million. During the same period in the previous year, the company posted $6.63 EPS. The company’s quarterly revenue was down 1.6% on a year-over-year basis. Equities research analysts predict that United Therapeutics Corporation will post 26.65 EPS for the current fiscal year.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.